14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
SIGA vs EBS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, SIGA Technologies Inc. (SIGA) captures the overall head-to-head institutional edge over Emergent Biosolutions, Inc. (EBS) on higher Unified Composite conviction (47.5/100 HOLD vs. 42.6/100 HOLD) after splitting the core matrix 5–5 (led by Growth & Scale, Options & Positioning), while EBS wins 3–2 across the 6-pillar growth and valuation breakdown. SIGA trades at $2.65 (2.5x Forward P/E, -14.2% operating margin) versus EBS at $5.15 (19.3x Forward P/E, 5.8% operating margin).
Growth vs. Quality Trade-Off: SIGA earns the overall head-to-head edge with a stronger Unified Composite Score (47.5/100 HOLD vs. EBS 42.6/100 HOLD) and 0.75β · 65% Vol risk profile, whereas EBS leads top-line expansion (-52.4% YoY revenue growth, 0.38x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: SIGA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0); meanwhile EBS is in a Breakdown options structure phase (RSI 29.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $282.8M market capitalization and 5.8% operating margin.
OpEx & R&D Reinvestment37.6% of Rev ($244M)
90D Engineering Disclosures0 Published
Investor FAQ SIGA vs EBS Key Questions & Quantitative Answers
As of Nov 19, 2026, SIGA Technologies Inc. (SIGA) captures the overall head-to-head institutional edge over Emergent Biosolutions, Inc. (EBS) on higher Unified Composite conviction (47.5/100 HOLD vs. 42.6/100 HOLD) after splitting the core matrix 5–5 (led by Growth & Scale, Options & Positioning), while EBS wins 3–2 across the 6-pillar growth and valuation breakdown. SIGA trades at $2.65 (2.5x Forward P/E, -14.2% operating margin) versus EBS at $5.15 (19.3x Forward P/E, 5.8% operating margin). Growth vs. Quality Trade-Off: SIGA earns the overall head-to-head edge with a stronger Unified Composite Score (47.5/100 HOLD vs. EBS 42.6/100 HOLD) and 0.75β · 65% Vol risk profile, whereas EBS leads top-line expansion (-52.4% YoY revenue growth, 0.38x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: SIGA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0); meanwhile EBS is in a Breakdown options structure phase (RSI 29.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SIGA leads the Growth & Scale pillar: SIGA posts -49.7% YoY revenue growth and -65.3% YoY earnings growth on $52M TTM revenue (23.4% gross margin, -14.2% operating margin), compared with EBS at -52.4% YoY revenue growth and -93.8% YoY earnings growth on $649M TTM revenue (43.4% gross margin, 5.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SIGA cumulative revenue shifted -81.2% while EBS shifted -5.1%. In operating R&D and SG&A reinvestment, SIGA deploys 37.6% of Rev ($20M) (0 90-day corporate R&D disclosures) versus 37.6% of Rev ($244M) (0 disclosures) for EBS.
EBS screens cheaper on headline valuation multiples. SIGA trades at 2.5x Forward P/E, N/M Trailing P/E, 3.37x PEG, and 1.4x EV/Revenue (-22.1% FCF margin), whereas EBS trades at 19.3x Forward P/E, 19.3x Trailing P/E, 0.38x PEG, and 0.9x EV/Revenue (29.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SIGA (0.4% ROE) versus EBS (-58.2% ROE) capital efficiency.
In options market volatility and institutional positioning, SIGA carries 81.4% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.75β · 65% Vol realized risk). By comparison, EBS carries 84.5% implied volatility (5th %ile, Compressed (<25th %ile)), a 2.48x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.90β · 54% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.